In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK Tries to Mimic Real-World Biotech

Executive Summary

Not satisfied with its R&D experiments to date, GSK has taken its most radical step yet toward re-creating biotech within its walls: even smaller units complete with investment boards occupied by external VCs and CEOs and milestone-based funding and external VCs.

Related Content

Back To School: Big Pharmas Test New Models For Tapping Academia
Putting The Pieces Together Again: GSK Creates End-To-End Business Units
GSK's Virtual-Proof-of-Concept Unit in Tune with Lilly's Chorus
New Frontiers in Pharma R&D Investment
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2009
Actelion Follows Innovation into GP Markets
Pfizer/Wyeth: Industrializing Pharma?
Pfizer's Increasingly Specialist Focus
Pharma's Strategic Divide: Focus or Diversify
GSK's Risk-Sharing Deals to Compete with In-House R&D


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts